PinCell
Proprietary transgenic mouse produces human form of FasL protein
MILAN, ITALY / ACCESSWIRE / May 4, 2023 / PinCell, a biotechnology company developing a first-in-class therapy for rare and debilitating autoimmune skin diseases, announced the successful completion of two independent in-vivo studies of its lead candidate (PC111) using a proprietary transgenic mouse model expressing the human form of the target protein (FasL). PinCell is a spin-off of the University of Modena and Reggio Emilia and was seed financed by Sofinnova Partners, a leading European venture capital firm based in Paris, London and Milan.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.PinCell's monoclonal antibody, PC111, proved effective in the neonatal passive pemphigus mouse model, considered the gold standard for testing treatments of pemphigus, a rare and debilitating skin disease marked by extreme blistering of skin and mucosae. Using the proprietary transgenic mouse, PC111 inhibited the production of blisters by at least 80%, confirming previous studies in in-vitro and ex-vivo human models of pemphigus. PC111 was also shown to dose-dependently neutralize human FasL in another in-vivo setting involving the Concanavalin-A liver model, which induces an acute release of FasL into the blood.
"This is a great achievement for the company," said Dr. Antonino (Tony) Amato, Chief Executive Officer of PinCell. "It provides for the first time in-vivo proof of concept evidence of PC111 effect in a humanized disease setting."
"We feel a real sense of accomplishment," said Prof. Carlo Pincelli, founder and Chief Medical Officer at PinCell. "By developing a proprietary model, we have now shown that our antibody does indeed inhibit blister formation by binding specifically to the human target."
"What is more, the humanized FasL mouse model could prove to be a valuable tool to study the involvement of the Fas/FasL pathway in other diseases in which this pathway may play a key role in disease development and progression," Prof. Pincelli added.
About pemphigus
Pemphigus is a rare condition that affects about 300,000 patients worldwide. Conservatively, a treatment based on PC111 would be beneficial for over 30 percent of this population who are relapsing or refractory to first line treatments.
PinCell's therapy will be an alternative to steroids or immunosuppressants currently prescribed or under development. By acting downstream from the immune system, at the level of skin cells, PC111's innovative mode of action will contribute to the reduction or the avoidance of steroids/immunosuppressants, while showing a rapid onset of action.
About PinCell
PinCell is a biotechnology company targeting a novel pathological pathway to develop first-in-class anti-inflammatory therapies for the treatment of rare, severe and highly undertreated skin diseases. Based in Milan, Italy, PinCell was founded in October 2008 as an academic spin-off of the University of Modena and Reggio Emilia by the world-class dermatology experts Prof. Carlo Pincelli and Prof. Alessandra Marconi. PinCell received seed funding from Sofinnova Partners.
For more information, please visit: www.pincell.it
About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, France, with offices in London and Milan, the firm brings together a team of 40 professionals from all over Europe, the U.S. and Asia. The firm focuses on paradigm-shifting technologies alongside visionary entrepreneurs. Sofinnova Partners invests across the Life Sciences value chain as a lead or cornerstone investor, from very early-stage opportunities to late-stage/public companies. It has backed nearly 500 companies over more than 48 years, creating market leaders around the globe. Today, Sofinnova Partners has over €2 billion under management. For more information, please visit: sofinnovapartners.com
CONTACT: Tony Amato, MD - CEO, PinCell - a.amato@pincell.com - +39-334-6263471
SOURCE: PinCell
View source version on accesswire.com:
https://www.accesswire.com/752528/PinCell-Announces-2-Successful-In-Vivo-Studies-for-Breakthrough-Skin-Disease-Therapy
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Polaris Renewable Energy Declares Quarterly Dividend5.2.2025 07:50:00 CET | Press release
TORONTO, ON / ACCESS Newswire / February 5, 2025 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris Renewable Energy" or the "Company"), is pleased to announce that its board of directors has declared a quarterly dividend of US$0.15 per common share outstanding. This dividend will be paid on February 28th to shareholders of record at the close of business on February 17th. The dividend is an "eligible dividend" as designated for Canadian federal, provincial, and territorial income tax purposes. The board of directors of Polaris Renewable Energy remains committed to paying a quarterly dividend and will evaluate further dividend increases, as appropriate, going forward. About Polaris Renewable Energy Inc. Polaris Renewable Energy Inc. is a Canadian publicly traded company engaged in the acquisition, development, and operation of renewable energy projects in Latin America & the Caribbean. We are a high-performing and financially sound contributor to the energy transition. The Company's o
Preservica and Oyster IMS Partner to Future-Proof Microsoft 365 Data with Active Digital Preservation5.2.2025 04:00:00 CET | Press release
OXFORD, UK / ACCESS Newswire / February 5, 2025 / Preservica, the leader in Active Digital Preservation™ archiving, has today announced a partnership with Oyster IMS, an expert consultancy-led business serving transnational agencies, global enterprises, local authorities and SMEs. Oyster IMS is now an authorized reseller of Preservica's Enterprise and Preserve365® technology and will support Microsoft 365 customers adopting a strong information governance framework for high-value, long-term content and those preparing for AI implementations. As digital content continues to grow in volume and complexity, having a robust and secure foundation of instantly useable, reliable and trusted long-term data has become a strategic imperative, essential for cutting compliance risk and leveraging AI. This is the arena in which Oyster IMS works with a set of clients ranging from SMEs to multinationals, and from local authorities to international governmental bodies. "I'm delighted to establish a for
ToolsGroup Welcomes Supply Chain Leader Sean Elliott as Chief Executive Officer4.2.2025 15:15:00 CET | Press release
20-year industry veteran brings deep technical expertise and leadership to guide ToolsGroup's next phase of growth BOSTON, MA / ACCESS Newswire / February 4, 2025 / ToolsGroup, a global leader in supply chain and retail planning and optimization software, today announced the appointment of Sean Elliott as its new Chief Executive Officer, effective immediately. Elliott brings more than two decades of strategic leadership and technical expertise in supply chain software development and leadership to ToolsGroup. Most recently, he served as Co-CEO at Körber Supply Chain Software. At ToolsGroup, Elliott will focus on accelerating innovation, driving strategic business expansion, and strengthening its partnerships and ecosystem to deliver a best-in-class customer outcome and experience. "We are thrilled to welcome Sean to ToolsGroup," said Andrew Zbella, Principal at Accel-KKR and member of the Board of Directors. "His proven leadership, deep technical background and continued commitment to
Mallia Therapeutics and Northway Biotech Announce Partnership for the Manufacturing of Soluble CD83 Protein for Hair Loss Treatment4.2.2025 05:00:00 CET | Press release
With Northway Biotech's expertise in biologics manufacturing, Mallia aims to enter the multi-billion-dollar alopecia market by delivering a safe and effective topical sCD83 treatment designed to stimulate hair follicle formation and promote sustained hair growth. ERLANGEN, GERMANY AND VILNIUS, LITHUANIA / ACCESS Newswire / February 4, 2025 / Mallia Therapeutics ("Mallia"), a biopharmaceutical company developing novel treatments for hair loss, and Northway Biotech ("NBT"), a biologics Contract Development and Manufacturing Organization (CDMO), have announced a partnership for the development of the production process and manufacturing of Mallia's soluble CD83 protein (sCD83), a treatment aimed at promoting hair follicle formation and growth. Under the agreement, Northway Biotech will leverage its expertise in biologics manufacturing to develop the production process for the recombinant sCD83 protein for large-scale production, utilizing the Pichia pastoris expression system. This collab
IXOPAY Appoints Yasser Abou-Nasr as SVP of Product to Drive Execution and Scale4.2.2025 00:00:00 CET | Press release
Seasoned Fintech Leader Joins IXOPAY to Advance Product Innovation and Drive Scalable Growth in Payment Orchestration. LEHI, UT / ACCESS Newswire / February 4, 2025 / IXOPAY, a leading enterprise payment orchestration platform, announced the appointment of Yasser Abou-Nasr as SVP of Product. With over 16 years of senior product leadership in payments and fintech, Yasser joins IXOPAY to execute the company's strategic vision and scale its product offerings to meet the growing demand for seamless and secure payment solutions. Yasser brings a proven track record of driving product execution at scale, combined with deep expertise in product management, operational transformation, and the development of B2B SaaS platforms. His leadership will be instrumental in advancing IXOPAY's enterprise payment orchestration platform, enabling businesses worldwide to simplify, secure, and optimize their payment systems through scalable and flexible solutions. "Yasser's ability to execute and scale compl
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom